Vepdegestrant Tablets 100 mg, 200 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 100 mg, 200 mg

Reference Brands: Veppanu (Arvinas)

Category: Oncology Cancer Care

Vepdegestrant (Veppanu, Arvinas) is a once-daily tablet for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, approved by the US FDA in May 2026. It is the first approved PROTAC protein degrader. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.

Product Description:

Vepdegestrant is a PROTAC (proteolysis-targeting chimera). One end of the molecule binds the oestrogen receptor and the other recruits the cell's own protein-disposal machinery, so the receptor is tagged and destroyed rather than just blocked. It is the first medicine of this type to be approved, and it works against the ESR1-mutant receptors that make breast cancer resistant to aromatase inhibitors.

The US FDA approved vepdegestrant as Veppanu in May 2026 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one endocrine therapy. An ESR1 mutation test is needed before treatment. It is taken as a 200 mg tablet once a day.

Sourcing and licensing notes. Vepdegestrant is patented and there is no generic. We confirm registration status for each destination before quoting. We handle authorised-supply enquiries and connect developers and licensees interested in the molecule and the PROTAC class ahead of patent expiry.